Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus

Wang, Jiun‐Ling; Tang, Hung Jen; Hsieh, Pang‐Hsin; Chiu, Fang-Yao; Chen, Yen Hsu; Chang, Ming Chau; Huang, Ching Tai; Liu, Chang Pan; Lau, Yeu Jun; Hwang, Kao Pin; Ko, Wen Chien; Wang, Chen Ti; Liu, Cheng Yi; Liu, Chien Lin; Hsueh, Po-Ren

doi:10.1016/j.ijantimicag.2012.03.010

Cited by 32 publications

(22 citation statements)

References 66 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…69 Fusidic acid was recently recommended as an efficient antibiotic for the treatment of bone and joint infections caused by S. aureus and MRSA. 70 In our clinical practice, cefuroxim 1.5 g i.v., t.i.d. and fusidic acid (Fucidin) 500 mg p.o., t.i.d.…”

Section: Treatment Of Prosthesis-related Infectionsmentioning

confidence: 99%

Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms

et al. 2013

View full text Add to dashboard Cite

Prosthesis-related infection is a serious complication for patients after orthopedic joint replacement, which is currently difficult to treat with antibiotic therapy. Consequently, in most cases, removal of the infected prosthesis is the only solution to cure the infection. It is, therefore, important to understand the comprehensive interaction between the microbiological situation and the host immune responses that lead to prosthesis infections. Evidence indicates that prosthesis infections are actually biofilm-correlated infections that are highly resistant to antibiotic treatment and the host immune responses. The authors reviewed the related literature in the context of their clinical experience, and discussed the possible etiology and mechanism leading to the infections, especially problems related to bacterial biofilm, and prophylaxis and treatment of infection, including both microbiological and surgical measures. Recent progress in research into bacterial biofilm and possible future treatment options of prosthesis-related infections are discussed.

show abstract

Section: Treatment Of Prosthesis-related Infectionsmentioning

confidence: 99%

Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms

et al. 2013

View full text Add to dashboard Cite

show abstract

“…1) is an orally active bacteriostatic antibiotic with wide clinical usage in Europe and Australasia for the treatment of methicillin-resistant Staphylococcus aureus and, more recently, multiresistant Staphylococcus aureus strains (Vanderhelst et al, 2013;Hall et al, 2015). Furthermore, in countries where FA is available, chronic oral therapy with FA is routinely used in the treatment of Staphylococcus-mediated prosthetic joint infections among the elderly population (Aboltins et al, 2007;Wang et al, 2012). The widespread clinical use of FA in suppressive antibiotic therapy is also associated with several cases of life-threatening rhabdomyolysis (with fatalities) upon coadministration with the 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, atorvastatin and simvastatin (Wenisch et al, 2000;Yuen and McGarity, 2003;Burtenshaw et al, 2008;O'Mahony et al, 2008;Herring et al, 2009;Saeed and Azam, 2009;Collidge et al, 2010;Magee et al, 2010;Teckchandani et al, 2010;Kearney et al, 2012;Gabignon et al, 2013), and more recently, rosuvastatin (Cowan et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy

Eng

Scialis

Rotter

et al. 2016

Drug Metabolism and Disposition

View full text Add to dashboard Cite

Chronic treatment of methicillin-resistant Staphylococcus aureus strains with the bacteriostatic agent fusidic acid (FA) is frequently associated with myopathy including rhabdomyolysis upon coadministration with statins. Because adverse effects with statins are usually the result of drug-drug interactions, we evaluated the inhibitory effects of FA against human CYP3A4 and clinically relevant drug transporters such as organic anion transporting polypeptides OATP1B1 and OATP1B3, multidrug resistant protein 1, and breast cancer resistance protein, which are involved in the oral absorption and/or systemic clearance of statins including atorvastatin, rosuvastatin, and simvastatin. FA was a weak reversible (IC 50 = 295 6 1.0 mM) and time-dependent (K I = 216 6 41 mM and k inact = 0.0179 6 0.001 min 21) inhibitor of CYP3A4-catalyzed midazolam-19-hydroxylase activity in human liver microsomes. FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC 50 value of 157 6 1.0 mM and was devoid of breast cancer resistance protein inhibition (IC 50 > 500 mM). In contrast, FA showed potent inhibition of OATP1B1-and OATP1B3-specific rosuvastatin transport with IC 50 values of 1.59 mM and 2.47 mM, respectively. Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC 50 = 2.26 mM) and Oatp1b2 (IC 50 = 4.38 mM) transporters, which are responsible for rosuvastatin uptake in rat liver. The potent inhibition of human OATP1B1/OATP1B3 by FA could attenuate hepatic uptake of statins, resulting in increased blood and tissue concentrations, potentially manifesting in musculoskeletal toxicity.

show abstract

“…Two major FA resistance mechanisms, the alteration of the drug target site caused by mutations in fusA, encoding elongation factor G (EF-G) or rplF encoding ribosome protein L6, and the protection of the drug target site by FusB family proteins, including FusB, FusC, and FusD, were reported in S. aureus (8). In staphylococci, high-level FA resistance is usually associated with mutations in fusA, while low-level resistance is generally caused by plasmidmediated resistance genes, including fusB, fusC and fusD (29).…”

Section: Discussionmentioning

confidence: 99%

“…Fusidic acid (FA) is a valuable alternative to vancomycin for infections caused by multi-drug resistant staphylococci, especially MRSA infections (8)(9)(10). However, there is a significant trend towards increased FA resistance among staphylococci with increased duration of use.…”

Section: Introductionmentioning

confidence: 99%

Emergence of Staphylococcus epidermidis Clinical Isolates with Resistance to Both Mupirocin and Fusidic Acid

Lin

Chen

Jin

et al. 2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

show abstract

Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus

Cited by 32 publications

References 66 publications

Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms

Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms

The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy

Emergence of Staphylococcus epidermidis Clinical Isolates with Resistance to Both Mupirocin and Fusidic Acid

Contact Info

Product

Resources

About